中国生物制药:创新药占比有望不断提升 看好公司价值重估

华创证券
25 Jul

中国生物制药是中国领先的创新研究和研发驱动型医药集团,集团主要附属公司包括正大天晴药业、北京泰德制药、南京正大天晴制药等。公司于2000 年在香港联交所上市,公司及核心子公司连续多年获评“全球制药企业TOP50”、“中国医药工业企业百强”。公司营收从2020 年的236.47 亿元增长到2024 年的288.66 亿元;净利润则相对保持稳定,主要系创新药研发投入持续增加。仿制药业务稳定,集采风险已...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10